Full Press Release Details
Resignation/Appointment
of Company Secretary and Chief Financial Officer
Limited (ASX: IMC; NASDAQ: IMRN) advises, in accordance with ASX Listing Rule 3.16.1, that Mr Phillip Hains has resigned as
Chief Financial Officer and Company Secretary, effective 9 February 2026.
Board thanks Mr Hains for his valuable contribution to the Company since 2013 and wishes him well in his future endeavours.
Company is pleased to announce the appointment of Ms Olga Smejkalova as Company Secretary, effective 9 February 2026. In accordance
with ASX Listing Rule 12.6, Ms Smejkalova will be the person responsible for communication with the ASX on Listing Rule matters.
Ms Smejkalova brings extensive experience in corporate governance and compliance, and the Board looks forward to her contribution
Company is also pleased to announce the appointment of Mr Aaron Laurita as Chief Financial Officer, effective 9 February 2026.
Mr Laurita brings strong finance and commercial expertise, developed through his work across several sectors, and the Board looks
forward to his contribution in this role.
release has been authorised by the Directors of Immuron Limited.
Chief Executive Officer
orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers' diarrhea, a
digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan is a purified
tablet preparation of hyper-immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria
and prevent colonization and the pathology associated with traveler's diarrhea. In Australia, Travelan is a listed medicine
on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Traveler's Diarrhea, reduce
the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan is a licensed natural health product (NPN
80046016) and is indicated to reduce the risk of Traveler's Diarrhea. In the U.S., Travelan is sold as a dietary supplement
for digestive tract protection.
Immuron Limited (ASX:
IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal
antibodies for the treatment of inflammatory mediated and infectious diseases.
Immuron's proprietary
technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability
of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine IgG can withstand the
acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine
IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits directly to the bacteria found
there. The underlying nature of Immuron's platform technology enables the development of medicines across a large range of infectious
diseases. The platform can be used to block viruses or bacteria at mucosal surfaces such as the Gastrointestinal tract and neutralize
the toxins they produce.
For more information
Sign up to Immuron's
FORWARD-LOOKING STATEMENTS:
press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements
relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking
statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect
our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from
those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing
and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the
timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party
suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial
additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our
SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which
any such statement is based, except as required by law.